Latest news and press releases about Lexicon Pharmaceuticals, Inc. (LXRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain...
Price
| Price | $2.02 |
| Market Cap | $897M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.07 |
| EV / EBITDA | -18.63 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -40.40% |
| Return on Invested Capital | -23.00% |
| Return on Assets | -24.44% |
| Gross Margin | 98.85% |
| Operating Margin | -131.43% |
| Net Margin | -147.38% |
Related companies: ADCT · BCYC · CMPX · FDMT · FULC · GOSS · NMRA
Explore sector: Healthcare · Biotechnology
More sections of LXRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks